RT Journal Article
SR Electronic
T1 Proxalutamide Improves Lung Injury in Hospitalized COVID-19 Patients – an Analysis of the Radiological Findings of the Proxa-Rescue AndroCoV Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.01.21259656
DO 10.1101/2021.07.01.21259656
A1 Cadegiani, Flávio Adsuara
A1 do Nascimento Fonseca, Daniel
A1 do Nascimento Correia, Michael
A1 Barros, Renan Nascimento
A1 Onety, Dirce Costa
A1 Israel, Karla Cristina Petruccelli
A1 Guerreiro, Emilyn Oliveira
A1 Medeiros, José Erique Miranda
A1 Nicolau, Raquel Neves
A1 Nicolau, Luiza Fernanda Mendonça
A1 Cunha, Rafael Xavier
A1 Barroco, Maria Fernanda Rodrigues
A1 da Silva, Patrícia Souza
A1 de Souza Paulain, Raysa Wanzeller
A1 Thompson, Claudia Elizabeth
A1 Zimerman, Ricardo Ariel
A1 Wambier, Carlos Gustavo
A1 Goren, Andy
YR 2021
UL http://medrxiv.org/content/early/2021/07/13/2021.07.01.21259656.abstract
AB Introduction Antiandrogen are good candidates against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) due to the inhibition of its entry into host cells by the suppression of TMPRSS2, an enzyme that primes the SARS-CoV-2 spike (S) protein and is key for its cell entry. Proxalutamide is a second-generation nonsteroidal anti-androgen (NSAA) with strong activities on androgen receptor (AR) antagonism, suppression of AR nuclear expression, and downregulation of the membrane-attached angiotensin converting enzyme-2 (ACE2). The efficacy of proxalutamide was previously demonstrated for early COVID-19 patients, and has now demonstrated efficacy to reduce deaths in hospitalized COVID-19 patient in a double-blind, placebo-controlled randomized clinical trial (RCT). Whether radiological changes would follow the improvement in clinical outcomes with proxalutamide is not established. The present post-hoc analysis aims to evaluate whether proxalutamide improves lung injury observed through chest computerized tomography (CT) scans, in addition to the clinical improvement, thus providing further objective evidence of the drug response in COVID-19.Methods This is a post-hoc analysis of the radiological findings of a double-blinded, placebo-controlled, prospective, two-arm RCT (The Proxa-Rescue AndroCoV Trial) with all enrolled patients from the three participating institutions of the city of Manaus, Amazonas, Brazil, that had at least two chest CT scans during hospitalization. The quantification of lung parenchyma involvement was performed by independent board-certified radiologists with expertise in analysis of COVID-19 images, that were blind to the assigned intervention in the RCT. A first chest CT scan was performed upon randomization and a second CT scan was performed approximately five days later, whenever patient transportation was feasible.Results Of the 395 patients initially evaluated, 72 and 179 patients from the proxalutamide and placebo arms, respectively, were included (n=251). Baseline and clinical characteristics, interval between first and second chest CT scans, and percentage of lung parenchyma affected in the baseline chest CT scan were similar between groups. In the second chest CT scan, the percentage of lungs affected (Median – IQR) was 35.0% (25.0-57.5%) in the proxalutamide group versus 67.5% (50.0-80.0%) in the placebo group (p < 0.001). The absolute and relative change between the second and first chest CT scans (Median – IQR) were −15.0 percent points (p.p.) (−30.0 – 0.0p.p.) and −25.0% (−50.0 – 0.0%) in the proxalutamide group, respectively, and +15.0p.p. (0.0 − +30.0p.p.) and +32.7% (0.0 − +80.0%) in the placebo group, respectively (p < 0.001 for both absolute and relative changes).Conclusion Proxalutamide improves lung opacities in hospitalized COVID-19 patients when compared to placebo. (NCT04728802)Competing Interest StatementKintor Pharmaceuticals, Ltd. manufactures and plans to market proxalutamide, and has an investigational new drug (IND) application under United States Food and Drugs Administration to conduct a Phase 3 study for proxalutamide for COVID-19. Applied Biology, Inc. has patents pending regarding antiandrogen therapy for COVID-19. Dr. Goren is employee of Applied Biology, Inc. Dr. Cadegiani has served as a clinical director for Applied Biology, Inc. Dr. Wambier has served as an advisor to Applied Biology, Inc. The other authors have no conflict of interest to declare.Clinical TrialNCT04728802Funding StatementKintor Pharmaceuticals, Ltd. manufactures and plans to market proxalutamide, and has an investigational new drug (IND) application under United States Food and Drugs Administration to conduct a Phase 3 study for proxalutamide for COVID-19. Applied Biology, Inc. has patents pending regarding antiandrogen therapy for COVID-19. Dr. Goren is employee of Applied Biology, Inc. Dr. Cadegiani has served as a clinical director for Applied Biology, Inc. Dr. Wambier has served as an advisor to Applied Biology, Inc. The other authors have no conflict of interest to declare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The RCT was approved by Brazilian National Ethics Committee of the Ministry of Health, under the approval number 4.513.425 of the process number (CAAE) 41909121.0.0000.5553 (original name of the Ethics Committee: Comite de Etica em Pesquisa (CEP) do the Comite Nacional de Etica em Pesquisa (CONEP) do Ministerio da Saude - CEP/CONEP/MS). All data used for the present post-hoc analysis was entirely covered by the approval obtained with the Brazilian National Ethics Committee of the Ministry of Health (MS) (approval number 4.513.425).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data is available under request to the corresponding author.